Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...

FDA fast track designation facilitates expedited development of DPTX3186, recognizing its potential to address serious unmet medical needs in gastric cancer treatment. DPTX3186 gains FDA fast track ...

Epcoritamab, rituximab, and lenalidomide combination is approved for relapsed/refractory follicular lymphoma, marking a first in bispecific antibody second-line treatments. The EPCORE FL-1 study ...

Biomarkers such as homologous recombination deficiency (HRD) and prostate-specific membrane antigen (PSMA) can sway treatment ...

Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer ...

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its ...

DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Avelumab demonstrated a 17% objective response rate in advanced penile cancer, with durable responses but limited survival benefits. Avelumab shows modest, durable responses in advanced penile cancer, ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...